Latest Regulatory Decisions News

Gold Mountain has secured a 12-month exclusive right to acquire the historical Malhada do Angico tungsten mine in northeast Brazil, for staged consideration of up to R$3 million. The opportunity comes with encouraging but non-representative grab samples, pending approvals and a drilling program still awaiting permits.

NeuRizer has secured agreements worth AUD$12.7 million with Reliance Industries, offering a potential funding bridge for its coal-gasification technology. But the company’s FY2025 accounts show a larger loss, just $183,666 in year-end cash and a material dependence on continued funding and creditor support.

Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

Cygnus Metals’ proposed takeover by Central Asia Metals has been pushed into October after a required Kazakhstan regulatory approval remained outstanding. The revised timetable targets scheme implementation on 27 October, but the dates remain conditional.

West Cobar Metals has engaged Wallis Drilling for its first scandium-focused campaign at the Salazar project, with work targeted for October subject to approvals. The programme will test shallow saprolite for higher-grade scandium zones and extensions to existing rare earth and titanium dioxide resources.

Cygnus Metals shareholders delivered overwhelming proxy support for Central Asia Metals’ proposed takeover, but the transaction still faces a Kazakhstan regulatory decision and possible court-date delay. Final poll results were not included in the chairman’s address and are expected separately.

MAAS Group has received FIRB approval for the sale of its construction materials division to Heidelberg Materials Australia, leaving shareholder approval and an Asphalt Operators acquisition as the key remaining conditions. Settlement remains targeted for October 2026, with transaction terms unchanged.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Osmond Resources reported a A$7.61 million FY26 loss and warned of a material uncertainty over its ability to continue as a going concern, despite holding A$5.50 million in cash. The company is betting its Spanish Orión project can move from exploration into a resource estimate and scoping study in the coming months.

The Star Entertainment Group narrowed its net loss to $307 million in FY26, boosted by refinancing, operational improvements, and a joint venture exit, while navigating ongoing regulatory scrutiny and remediation efforts.